

COPD and Asthma Devices Market is Likely to Expand USD 6.3 Billion at 12.6% CAGR by 2031

PORTLAND, DE, UNITED STATES, January 29, 2025 /EINPresswire.com/ -- Day-to-day exposure to environmental pollution, increase in population susceptible to indoor air pollutants, portability of the drug delivery devices, rise in population of active smokers, and surge in government initiatives drive the growth of the global [COPD and asthma devices market](#). However, increase in price competition and deterioration of material quality, overall high cost of asthma treatment is a challenge for the patients, and incompetent reimbursement support impede the growth to certain extent. Conversely, patent expiration for blockbuster drug and smart Inhalers are anticipated to create lucrative opportunities for the key players in the industry.



The global COPD and asthma devices market is expected to reach \$51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027. Chronic obstructive pulmonary disease (COPD) and asthma devices are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. Moreover, COPD and asthma are the respiratory diseases that cause difficulty in breathing and a blockage in the airways of lungs. Furthermore, according to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

Request Sample Report at: <https://www.alliedmarketresearch.com/request-sample/579>

Day-to-day exposure to environmental pollution, increase in population susceptible to indoor air pollutants, portability of the drug delivery devices, rise in population of active smokers, and surge in government initiatives drive the growth of the global COPD and asthma devices market.

However, increase in price competition and deterioration of material quality, overall high cost of asthma treatment is a challenge for the patients, and incompetent reimbursement support impede the growth to certain extent. Conversely, patent expiration for blockbuster drug and smart Inhalers are anticipated to create lucrative opportunities for the key players in the industry.

Chronic obstructive pulmonary disease (COPD) and asthma are a chronic inflammatory lung disorder. The COPD and Asthma symptoms & causes are equivalent to the symptoms of the pandemic coronavirus disease 2019. In addition, asthmatic patients are more prone to the Covid-19 symptoms. According to the paper published by the Journal of Allergy and Clinical Immunology, in 2020, the patients with the asthma and COPD appear to have increased their adherence to inhalers medications during the Covid-19. Moreover, according to the National Health Service (NHS) in 2020, the number of inhalers prescribed by general practitioners in England increased by 63% between February 2020 and March 2020. Further, in some parts of the country such as U.K and U.S. are experiencing shortages of albuterol inhalers, because hospitals are using them more for COVID-19 patients. Thus, Covid-19 has uplifted the growth and opportunities for the manufacturers of COPD and Asthma devices during the forecast period.

The inhalers segment to dominate by 2027-

Based on type, the inhalers segment contributed to 96% of the global COPD and asthma devices market share in 2019, and is expected to rule the roost by the end of 2027. The inhalation route is the fastest and most effective method of delivering medications to the respiratory system during treatment of COPD and asthma, which drives the growth of the segment. At the same time, the nebulizers segment would register the fastest CAGR of 4.7% throughout the forecast period. Driver??

The retail pharmacies segment to maintain the dominant share-

Based on application, the retail pharmacies segment accounted for nearly half of the global COPD and asthma devices market revenue in 2019, and is anticipated to lead the trail from 2020 to 2027. Retail pharmacies are the oldest and most conventional medium for distributing the respiratory devices to the consumers, owing to its large chain of distribution network of pharmacies store. This factor has propelled the segment growth. Simultaneously, the online pharmacies segment would manifest the fastest CAGR of 6.0% till 2027.

For Purchase Enquiry at: <https://www.alliedmarketresearch.com/purchase-enquiry/579>

North America garnered the major share in 2019 –

Based on geography, North America garnered the largest share in 2019, holding more than one-third of the global COPD and asthma devices market. This is owing to the widespread and early adoption of inhalers & nebulizers and large pool of patients suffering from respiratory diseases

in this region. However, the region across Asia-Pacific would portray the fastest CAGR of 5.0% by 2027, due to rise in healthcare expenditure, growth in awareness of advanced portable COPD & asthma devices, and increase in disposable income in Asia-Pacific region.

Key players in the industry-

GF Health Products
GlaxoSmithKline Plc
Koninklijke Philips N.V.
Novartis AG
PARI medical Holding GMBH
Smith's Group Plc.
Aerogen, Inc.
AstraZeneca PLC
Baxter International Inc.
Boehringer Ingelheim International GmbH
3M COMPANY

Trending Reports in Healthcare Industry:

Vascular Graft Market <https://www.alliedmarketresearch.com/vascular-graft-market>

Cancer Gene Therapy Market <https://www.alliedmarketresearch.com/cancer-gene-therapy-market>

Biomarkers Market <https://www.alliedmarketresearch.com/biomarkers-market>

RNA Based Therapeutics Market <https://www.alliedmarketresearch.com/rna-based-therapeutics-market>

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging

out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+ +1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/781244574>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.